Granules India Q1 FY25 results (Apr–Jun 2024) and concall

Granules India delivered a robust Q1 FY25 performance, primarily driven by strong growth in its formulations segment and new product launches. While the Paracetamol market faces near-term headwinds, the company's strategic shift towards a diversified, formulation-led portfolio and expansion in key markets like the US is paying off. Investments in R&D and capacity expansion are ongoing, despite some initial challenges in the CZRO project.